| For: | Wu DD, He XF, Tian C, Peng P, Chen CL, Liu XH, Pang HJ. Tumor-feeding artery diameter reduction is associated with improved short-term effect of hepatic arterial infusion chemotherapy plus lenvatinib treatment. World J Gastroenterol 2022; 28(26): 3232-3242 [PMID: 36051348 DOI: 10.3748/wjg.v28.i26.3232] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v28/i26/3232.htm |
| Number | Citing Articles |
| 1 |
Haohao Lu, Ya Gao, Xiangwen Xia, Qing Fu, Dongqiao Xiang. RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma. BMC Cancer 2025; 25(1) doi: 10.1186/s12885-025-14274-x
|
| 2 |
Xing Lv, Peng-Bo Zhang, Er-lei Zhang, S. Yang. Predictive factors and prognostic models for Hepatic arterial infusion chemotherapy in Hepatocellular carcinoma: a comprehensive review. World Journal of Surgical Oncology 2025; 23(1) doi: 10.1186/s12957-025-03765-7
|
| 3 |
Susumu Maruta, Yohei Koshima, Yuji Debari, Chihei Sugihara, Gou Takahata, Ryo Tamura, Tadashi Ohshima, Yuji Ono, Yuho Morita, Tomoki Chiba, Satoru Ishida, Hideto Imai, Keisuke Watanabe, Ryo Chinzei, Masanori Takahashi, Yoshihiko Ooka. Lenvatinib Combined with New FP Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma: Clinical Efficacy, Vascular Remodeling, and Implications for Immuno-Oncology–Systemic Combination Therapy. Current Oncology 2026; 33(5): 286 doi: 10.3390/curroncol33050286
|
| 4 |
Himawari Asanuma, Teppei Okamoto, Tadashi Yoshizawa, Takuya Oishi, Tomoko Hamaya, Hirotake Kodama, Takuma Narita, Jotaro Mikami, Naoki Fujita, Tohru Yoneyama, Hayato Yamamoto, Atsushi Imai, Chikara Ohyama, Shingo Hatakeyama. CT-based renal artery caliber change as a potential imaging marker of treatment response in renal cell carcinoma; an exploratory imaging study. Cancer Imaging 2026; 26(1) doi: 10.1186/s40644-026-01023-x
|
| 5 |
Yuhang Chen, Suoyi Dai, Chien-shan Cheng, Lianyu Chen. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. Journal of Hematology & Oncology 2024; 17(1) doi: 10.1186/s13045-024-01647-1
|